News
Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...
Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...
Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.
Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...
Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...
Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.
The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with ...
Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...
The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.
The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...
GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...
On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results